This Myc‐mediated glycolysis enhancement favors glucose addiction and renders GBM cells vulnerable to glycolytic inhibitors in patient‐derived GBM tumorspheres and in orthotopic GBM xenografts [78]. The gene discussed is MYC; the disease is glioblastoma.